AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20864946
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) treatment
Trial: 18294107
Drug: Montelukast 5-10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 5-10 mg/day for 3-7 days
Trial: 18294107
Drug: Albuterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (2 puffs of metered-dose inhaler just before exercise challenge)
Trial: 16087295
Drug: Intradermal capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal capsaicin injections
Trial: 16087295
Drug: Intradermal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal saline placebo injections
Trial: 12407092
Drug: Silver diamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver diamine fluoride solution (44,800 ppm F) applied annually
Trial: 12407092
Drug: Silver diamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver diamine fluoride solution (44,800 ppm F) applied annually after removal of soft carious tissues
Trial: 10092314
Drug: Oxygen supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen supplementation (12 L/min for 9 hours)
Trial: 7602344
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy containing cyclophosphamide
Trial: 2379530
Drug: Domperidone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (15 mg) followed by Pergolide (25 micrograms) after 1 hour
Trial: 2379530
Drug: Domperidone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (15 mg) followed by Placebo after 1 hour
Trial: 31981856
Drug: Serial ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial ketamine infusions
Trial: 23403945
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion with 100 ml 5% dextrose/h
Trial: 23403945
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (100 ml/h)
Trial: 23403945
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline (100 ml/h)
Trial: 21054229
Drug: Simultaneous sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous sinus mucosal lining elevation and placement of dental implants without graft materials
Trial: 21054229
Drug: Simultaneous sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous sinus mucosal lining elevation and placement of dental implants with intraoral autogenous bone graft
Trial: 20217948
Drug: Positive attitude
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Positive attitude towards medication
Trial: 20217948
Drug: Medication knowledge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication knowledge
Trial: 17124283
Drug: Risedronate 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 2.5 mg/day (group B)
Trial: 11513817
Drug: 100-g amino
RxNorm normalized name: L-a-Amino-g-methylthiobutyric acid
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100-g amino acid (AA) drink devoid of tryptophan
Trial: 9635910
Drug: Piperacillin/tazobactam 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 4 g i.v. Q6H
Trial: 9635910
Drug: Imipenem 500
RxNorm normalized name: imipenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem 500 mg i.v. Q6H
Trial: 3124598
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) for 10 days
Trial: 31609293
Drug: LBW protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBW protocol (679 mg iodine/kg for men, 762 mg iodine/kg for women)
Trial: 31609293
Drug: LBW protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBW protocol (620.7 mg iodine/kg)
Trial: 29151034
Drug: placebo/simvastatin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo/simvastatin 40 mg
Trial: 24882567
Drug: Psilocybin (.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (.16 mg/kg)
Trial: 14567819
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 100 mug
Trial: 11126207
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg t.i.d. during the first year
Trial: 11126207
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg t.i.d. during the second year
Trial: 8246033
Drug: Gallium nitrate
RxNorm normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gallium nitrate treatment (30 mg/m2/d for 2 weeks, followed by 2 weeks off, plus 100 mg/m2/d IV for 5 days every other month)
Trial: 8246033
Drug: Gallium nitrate
RxNorm normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gallium nitrate treatment
Trial: 3513669
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg bid
Trial: 23507369
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg fluoxetine and high dose folic acid (5 mg/day; n=19; Group II)
Trial: 23507369
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg fluoxetine and low dose folic acid (1.5 mg/day; n=23; Group I)
Trial: 16027695
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (moderate pressure)
Trial: 1629748
Drug: 160/800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160/800 mg b.i.d. orally x 3 days
Trial: 1629748
Drug: 160/800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160/800 mg i.m. x 10 days
Trial: 1629748
Drug: 160/800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160/800 mg b.i.d. orally x 20 days
Trial: 6396117
Drug: Bifonazole solution
RxNorm normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole solution (daily for 2 weeks)
Trial: 6396117
Drug: Selenium sulphide
RxNorm normalized name: Selenium sulphide
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selenium sulphide shampoo (2.5% daily for 1 week and weekly for 6 weeks)
Trial: 27941065
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Atorvastatin and Evolocumab
Trial: 25943660
Drug: Acetaminophen (ACT)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (ACT) 20 mg/kg
Trial: 25128046
Drug: Half-dose etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Half-dose etanercept (25 mg/wk)
Trial: 25128046
Drug: Full-dose etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Full-dose etanercept (50 mg/wk)
Trial: 1759956
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy with exposure and response prevention (CBT + ERP)
Trial: 7047984
Drug: Acarbose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (100 mg p.o.)
Trial: 7047984
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mg p.o.)
Trial: 26853953
Drug: Prompt revascularization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt revascularization (PR) with intensive medical therapy (IMT)
Trial: 24045979
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (600 μg)
Trial: 24045979
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (10 IU)
Trial: 20977608
Drug: Partial overdentures
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial overdentures supported with single immediately loaded implant in symphyseal region
Trial: 17141741
Drug: Cholinergic medication
RxNorm normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic medication (acetylcholinesterase inhibitor)
Trial: 17141741
Drug: REM sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REM sleep augmentation (physiological rebound)
Trial: 12221896
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray, 200 mcg once daily
Trial: 7828381
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg S‐nitrendipine
Trial: 7828381
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg racemic nitrendipine
Trial: 7828381
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg R‐nitrendipine
Trial: 7828381
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg R‐nitrendipine
Trial: 17398308
Drug: EPA (eicosapentaenoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (eicosapentaenoic acid) 1800 mg daily with statin
Trial: 16146489
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day topiramate
Trial: 16146489
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day topiramate
Trial: 10363865
Drug: Subcutaneous ardeparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ardeparin 50 anti-Xa U/kg (low dose)
Trial: 10363865
Drug: Subcutaneous ardeparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ardeparin 100 anti-Xa U/kg (high dose)
Trial: 10363865
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (including ardeparin and placebo)
Trial: 6183631
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of certain foodstuffs correlated to oral ulceration
Trial: 31112379
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg, administered orally twice daily
Trial: 26945186
Drug: 1000 μg anisodamine
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 μg anisodamine
Trial: 26945186
Drug: 2000 μg anisodamine
RxNorm normalized name: Anisodamine
DrugBank: Anisodamine (DB11785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 μg anisodamine
Trial: 26945186
Drug: 4000 μg anisodamine
RxNorm normalized name: methylcellulose
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 μg anisodamine
Trial: 17665604
Drug: Fenspiride (anti-inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenspiride (anti-inflammatory drug)
Trial: 7598067
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement (increased average calcium intake by 17.9 mmol/d or 714 mg/d)
Trial: 29347
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate preparation (Citro‐Soda; Abbott) 4 g single dose
Trial: 29347
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate preparation (Citro‐Soda; Abbott) 12 g single dose
Trial: 29347
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate preparation (Citro‐Soda; Abbott) 4 g and 12 g doses after 3-6 days of continuous therapy every 6 hours
Trial: 27447966
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC = 5, day 2) plus Paclitaxel (175 mg/m2, day 1)
Trial: 27447966
Drug: Epirubicin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (75 mg/m2, day 1) plus Paclitaxel (175 mg/m2, day 2)
Trial: 21121410
Drug: salbutamol 2
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol 2 mg + bromhexine HCI 8 mg + guaiphenesin 100 mg (group A)
Trial: 21121410
Drug: salbutamol 2
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol 2 mg + guaiphenesin 100 mg (group B)
Trial: 21121410
Drug: salbutamol 2
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol 2 mg + bromhexine 8 mg (group C)
Trial: 17951945
Drug: Omega-3 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (2 gm pearls per day, given in two equal doses)
Trial: 2273081
Drug: Moxonidine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.25 mg)
Trial: 24392848
Drug: Salmeterol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (100 μg twice daily)
Trial: 12517686
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (NA) infusion
Trial: 10648307
Drug: Esmolol (ESM)
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esmolol (ESM) 1.0 mg/kg
Trial: 10648307
Drug: Combination (COMB)
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (COMB) of NIC and ESM (one-half dose each)
Trial: 16286672
Drug: HMB/KIC (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB/KIC (3 g HMB and 0.3 g alpha-ketoisocaproic acid, daily)
Trial: 12000379
Drug: CDP850 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP850 (20 mg kg-1 intravenously as a single dose)
Trial: 9865985
Drug: Oral cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cefixime 200 mg combined with probenecid 500 mg three times daily for 100 days
Trial: 9865985
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone 2 g daily for 14 days followed by oral amoxicillin 500 mg combined with probenecid 500 mg three times daily for 100 days
Trial: 809253
Drug: Oral TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TRH
Trial: 12884360
Drug: Altered lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Altered lipid diets (fish oil supplement or seafood diet)
Trial: 10833208
Drug: Methotrexate 15
RxNorm normalized name: methotrexate 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 15 mg intramuscularly once weekly for 40 weeks
Trial: 10833208
Drug: Methotrexate 15
RxNorm normalized name: methotrexate 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 15 mg intramuscularly once weekly
Trial: 8799522
Drug: Sinemet CR
RxNorm normalized name: Sinemet CR
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sinemet CR (levodopa 200 mg/carbidopa 50 mg)
Trial: 8799522
Drug: Sinemet-Plus (levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet-Plus (levodopa 100 mg/carbidopa 25 mg)
Trial: 8799522
Drug: Benzhexol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzhexol (2 mg tablets)
Trial: 1483496
Drug: Oral famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral famotidine (40 mg)
Trial: 31037285
Drug: Aflibercept (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (2.0 mg intravitreous injection every 4 weeks)
Trial: 27977439
Drug: Bilateral sternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sternal infusion of 0.2% ropivacaine (3 ml/h through each catheter)
Trial: 27977439
Drug: Bilateral sternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sternal infusion of 0.2% ropivacaine
Trial: 18575355
Drug: Specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific treatment (computer cognitive rehabilitation) consisting of 12 individual sessions of computer exercises
Trial: 18575355
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (aspecific treatment) consisting of semi-structured interviews with patients
Trial: 3183034
Drug: Lymphoblastoid interferon
RxNorm normalized name: interferon alfa-n1 lymphoblastoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphoblastoid interferon administered daily for 6 months
Trial: 31615466
Drug: Sequential HAIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential HAIC with cisplatin followed by sorafenib
Trial: 27671836
Drug: 2-hourly feeding
RxNorm normalized name: BAGS,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hourly feeding
Trial: 27671836
Drug: 3-hourly feeding
RxNorm normalized name: SYRINGE,FEEDING ENFIT 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-hourly feeding
Trial: 11097146
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) 100 mg twice daily for one week
Trial: 9067912
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of treatment after 4 years
Trial: 9067912
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (N = 20) with largest initial treatment-induced fall in GFR
Trial: 9067912
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of treatment in Group A
Trial: 9067912
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of treatment in Group B
Trial: 9067912
Drug: Post-treatment GFR
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment GFR in Group A
Trial: 9067912
Drug: Post-treatment GFR
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment GFR in Group B
Trial: 3716914
Drug: Cigarette smoking
RxNorm normalized name: Cigarette smoking tobacco
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette smoking and caffeine administration during task performance
Trial: 24720741
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 1600 µl
Trial: 24720741
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 1200 µl
Trial: 24720741
Drug: Thigh injections
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thigh injections
Trial: 11836328
Drug: High-dose testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose testosterone (200 mg) in older men
Trial: 11836328
Drug: Low-dose testosterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose testosterone (100 mg) in young men
Trial: 8907566
Drug: Alpha-interferon treatment
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpha-interferon treatment
Trial: 1919966
Drug: Prism adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism adaptation preoperative treatment
Trial: 7128838
Drug: Danazol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (800 mg daily for the first 2 months, 600 mg daily for the next 2 months, and 400 mg daily for the final 2 months)
Trial: 10213347
Drug: Glimepiride (1.162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1.162 mg)
Trial: 10213347
Drug: Glibenclamide (2.54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (2.54 mg)
Trial: 14317
Drug: Dipotassic chlorazepate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipotassic chlorazepate, paracetamol and codeine (individual components)
Trial: 17350342
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment with AEDs
Trial: 12358962
Drug: Multimodal anti-emetic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal anti-emetic prophylaxis including total intravenous anaesthesia with propofol, high fractional inspired oxygen (80%), omission of nitrous oxide, dexamethasone 8 mg, haloperidol 10 microg.kg(‐1), and tropisetron 2 mg.